Genetic defects and therapy in Laron syndrome and similar conditions;VEKSTHORMONINSENSITIVITET. GENETISKE DEFEKTER OG TERAPI VED LARONS SYNDROM OG LIGNENDE TILSTANDER

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 7, 1997, Pages 948-951

  Vesterhus, Per ^a  

^a Barneavdelingen   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ARTICLE; CASE REPORT; CHILD; FEMALE; GENETIC DISORDER; GENETIC HETEROGENEITY; GROWTH RATE; HUMAN; LARON SYNDROME; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

BODY HEIGHT; CHILD; DRUG RESISTANCE; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; RECEPTORS, SOMATOTROPIN; SYNDROME;

EID: 0031058145     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Laron Z. Prismatic cases: Laron syndrome (primary growth hormone resistance) from patient to laboratory to patient. J Clin Endocrinol Metab 1995; 80: 1526-31.
2. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB et al. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-1 in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-8.
3. Savage MO, Carlsson LMS, Chatelain PG, Ranke MB, Rosenfeld RG. Growth hormone insensitivity syndromes. Acta Paediatr Suppl 1995; 411: 87-90.
4. Blum WF, Cotteril AM, Postel-Vinay MC, Ranke MB, Savage MO, Wilton P. Improvement of diagnostic criteria in growth hormone insensitivity syndrom: solutions and pitfalls. Acta Paediatr Suppl 1994; 399: 117-24.
5. Klinger B, Laron Z. Three year IGF-1 treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-58.
6. Berg MA, Argente J, Chernausek S, Gracia R, Guevaro-Aguirre J, Hopp M et al. Diverse growth hormone receptor gene mutations in Laron syndrome. Am J Hum Genet 1993; 52: 998-1005.
7. Ranke MB, Wilton P. Adverse events during treatment with recombinant insulin-like growth factor 1 in patients with growth hormone insensitivity. Acta Paediatr Suppl 1994; 339: 143-5.
8. Hindmarsh PC, Brook CDG. Final height of short normal children treated with growth hormone. Lancet 1996; 348: 13-6.
9. Hintz RL, Goddard A, Attie KM, Baptista J, Chernausek S, Geffner M et al. GH receptor mutations in children with idiopathic short stature. Horm Res 1996; 46 (suppl 2): 6.
10. Bjerknes R, Vesterhus P, Aarskog D. Increased neutrophil insulin-like growth factor (IGF-1) receptor expression and IGF-1 induced functional capacity in patients with untreated Laron syndrome. Eur J Endocrinol 1996; akseptert for publisering.
11. Han VKM. Is the central nervous system a target for growth hormone and insulin-like growth factors? Acta Paediatr Suppl 1995; 411: 3-8.